Biosimilars as antivirals: scientific and regulatory readiness for rapid, cost-effective deployment in infectious threats
{{output}}
Introduction: Rapid and equitable access to antiviral biologics in outbreaks is constrained by bespoke manufacturing, lengthy trials, and uneven procurement. Biosimilar antivirals could change responsiveness from single-source su... ...
